Legal & General Group
TRDA icon

Legal & General Group’s Entrada Therapeutics TRDA Stock Holding History

Legal & General Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8K Hold
2,557
– – ﹤0.01% 3150
2026
Q1 		$32.3K Hold
2,557
– – ﹤0.01% 2809
2025
Q4 		$26.3K Hold
2,557
– – ﹤0.01% 2922
2025
Q3 		$14.8K Hold
2,557
– – ﹤0.01% 3171
2025
Q2 		$17.2K Sell
2,557
-17,342
-87% -$140K ﹤0.01% 3071
2025
Q1 		$180K Hold
19,899
– – ﹤0.01% 2625
2024
Q4 		$344K Buy
19,899
+4,175
+27% +$75.6K ﹤0.01% 2580
2024
Q3 		$251K Buy
15,724
+876
+6% +$13.8K ﹤0.01% 2643
2024
Q2 		$212K Buy
14,848
+3,786
+34% +$53.8K ﹤0.01% 2658
2024
Q1 		$157K Hold
11,062
– – ﹤0.01% 2709
2023
Q4 		$167K Hold
11,062
– – ﹤0.01% 2722
2023
Q3 		$175K Sell
11,062
-239
-2% -$3.76K ﹤0.01% 2745
2023
Q2 		$171K Buy
11,301
+7,727
+216% +$106K ﹤0.01% 2764
2023
Q1 		$51.8K Buy
3,574
+637
+22% +$8.51K ﹤0.01% 2869
2022
Q4 		$39.7K Buy
+2,937
New +$51.5K ﹤0.01% 2979
2022
Q2 		– Sell
-848
Closed -$8K – 3654
2022
Q1 		$8K Hold
848
– – ﹤0.01% 3454
2021
Q4 		$15K Buy
+848
New +$20.6K ﹤0.01% 3368

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Legal & General Group's TRDA Position: Q2 2026 in Review

Legal & General Group held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 2,557 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3150.

Legal & General Group first reported a position in TRDA in Q4 2021 and has held it in 17 quarters since. The position peaked at $344K in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Legal & General Group held 2,557 shares of Entrada Therapeutics worth $18.8K as of Q2 2026.
  • Legal & General Group left its Entrada Therapeutics share count unchanged in Q2 2026.
  • Entrada Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3150 holding.
  • Legal & General Group first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Legal & General Group's Entrada Therapeutics position peaked at $344K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.